Skip to main content
. 2024 Jan 10;11:1338862. doi: 10.3389/fpubh.2023.1338862

Table 4.

Proportional reporting ratios in completed primary series.

Symptoms Completed primary series
Specific AEs of COVID-19 vaccines PRR 95% CIL 95% CIH
Hearing loss 4,319 1.554 1.487 1.625
Tinnitus (Ringing in the ears) 12,338 2.343 2.275 2.413
Ear infections (Otitis Media) 563 0.227 0.207 0.248
Meniere’s disease 82 1.945 1.382 2.736
Vestibular neuronitis 98 1.217 0.924 1.603
Dizziness or vertigo 71,255 1.629 1.612 1.647
Sinusitis 1,333 0.832 0.777 0.891
Rhinitis (Allergic and Non-allergic) 126 0.056 0.047 0.067
Epistaxis 2,085 1.605 1.506 1.712
Anosmia 3,652 3.167 2.983 3.363
Nasal polyps 15 1.956 0.879 4.355
Snoring or difficulty breathing through the nose and sleep apnea 494 0.205 0.186 0.225
Allergies 5,983 0.251 0.244 0.258
Tonsillitis 73 0.491 0.375 0.642
Laryngitis 135 0.332 0.275 0.401
Vocal cord polyps and nodules 27 1.101 0.659 1.837
Laryngopharyngeal reflux (Acid Reflux) 337 2.632 2.187 3.168
Epiglottitis 8 0.348 0.159 0.759
Pharyngitis 3,730 0.573 0.551 0.596
Any IR 106,653
Sample size 226,593,618

Data are from the VAERS and CDC Covid-19 vaccinations data tracker through to August 30, 2023. PRR, proportional reporting ratio.